List of patients on Originator/Innovator Biologics for transition to Biosimilars

Last Updated November 28, 2025

The Ontario government is expanding its drug coverage policy to further promote the use of biosimilars funded through the Ontario Drug Benefit (ODB) program. As of November 28, 2025, ODB patients who are currently on Eylea®, Xolair® and/or Actemra® must transition to a Health Canada approved biosimilar equivalent by May 28, 2026 or by the expiry date of their existing Exceptional Access Program (EAP) approval (if applicable) to maintain coverage under ODB, unless they have an approved medical exemption.

For more information, please refer to the Ministry of Health INFOBulletin.

To assist clinicians, OntarioMD has developed queries for Accuro® EMR, OSCAR Pro, and TELUS PSS to identify your patients who have been prescribed products affected by the new biosimilars policy. You can easily download, import and run these queries to produce a report of patients on any of the following products:

Added November 28, 2025:

  • Eylea®
  • Xolair®
  • Actemra®

Your next step is to check whether these patients have one or more biologics that are currently covered by ODB. To do this, you can access the provincial DHDR (Digital Health Drug Repository) directly from your EMR. You launch the DHDR from the patient’s chart in your EMR to view publicly funded drugs dispensed in Ontario and paid by the Ontario Drug Benefit (ODB) program. These include the ones listed in the Formulary or approved through the Exceptional Access Program (EAP). Alternatively, you can manually cross-check the patient list generated by the query with DHDR via the Connecting Ontario portal.

Get more information or sign up for DHDR.

TELUS PSS Search for patients on originator biologics.
Originator/Innovator Biologics for transition to Biosimilar
Note this search will look for patients with current active medications of Eylea®, Xolair® and Actemra®

OSCAR Pro Report by Template for patients on originator biologics.
List of patients on Originator/Innovator Biologics for transition to Biosimilars
Note this search will look for patients with current active medications of Eylea®, Xolair® and Actemra®

QHR Accuro Query “List of patients on Originator/Innovator Biologics for transition to Biosimilars Updated Nov 2025” available in the Accuro© Alert Definition Publisher for download.  Assistance with the Accuro© Query Builder.
Note this search will look for patients with current active medications of Eylea®, Xolair® and Actemra®.

Need help Downloading or importing tools to your EMR?
Click HERE to REVIEW ‘HOW To’ Resources